Profile data is unavailable for this security.
About the company
Beijing Sun Novo Pharmaceutical Research Co Ltd is a China-based company that provides research and development outsourcing services for pharmaceutical companies. The Company's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)951.95m
- Net income in CNY209.57m
- Incorporated2009
- Employees1.37k
- LocationBeijing Sun-Novo Pharmaceutical Research Co Ltd1F, Building 7, No. 79Shuangying West Road, Science ParkChangping DistrictBEIJING 102200ChinaCHN
- Phone+86 1 060748199
- Fax+86 1 060748199
- Websitehttp://sun-novo.com
Mergers & acquisitions
| Acquired company | 688621:SHH since announced | Transaction value |
|---|---|---|
| Chengdu Sintanovo Biotechnology Co Ltd | -32.64% | 16.43m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.63bn | 193.23m | 5.20bn | 1.69k | 26.74 | 3.39 | -- | 3.19 | 0.4428 | 0.4428 | 3.72 | 3.49 | 0.5227 | 1.48 | 6.56 | 966,866.90 | 5.93 | 5.39 | 9.72 | 9.37 | 67.75 | 66.91 | 11.34 | 8.95 | 0.5527 | 16.41 | 0.3447 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 799.09m | 269.00m | 5.45bn | 1.14k | 19.64 | 2.35 | -- | 6.82 | 1.37 | 1.37 | 4.08 | 11.49 | 0.2573 | 0.9016 | 6.83 | 699,118.90 | 8.66 | 10.04 | 10.48 | 11.63 | 81.31 | 83.66 | 33.66 | 28.29 | 3.33 | -- | 0.2547 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Innovita Biological Technology Co Ltd | 625.12m | 266.22m | 5.49bn | 404.00 | 20.63 | 2.76 | -- | 8.78 | 1.96 | 1.96 | 4.59 | 14.62 | 0.3093 | 1.67 | 6.23 | 1,547,324.00 | 13.17 | -- | 14.20 | -- | 80.99 | -- | 42.59 | -- | 10.66 | -- | 0.0015 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 336.56m | 135.71m | 5.53bn | 43.00 | 40.76 | 3.69 | -- | 16.45 | 0.66 | 0.66 | 1.64 | 7.28 | 0.2219 | 0.9416 | 3.28 | 7,826,913.00 | 8.95 | -0.9181 | 9.39 | -0.9485 | 93.54 | 93.19 | 40.32 | -6.11 | 12.66 | -- | 0.0342 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 951.95m | 209.57m | 5.55bn | 1.37k | 26.46 | 5.47 | -- | 5.83 | 1.87 | 1.87 | 8.50 | 9.06 | 0.5465 | 26.19 | 1.77 | 694,854.30 | 11.70 | 12.99 | 19.13 | 21.70 | 59.10 | 53.93 | 21.40 | 21.34 | 1.77 | 45.00 | 0.3721 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
| Pulike Biological Engineering Inc | 1.18bn | 136.36m | 5.87bn | 1.68k | 42.96 | 2.14 | -- | 4.96 | 0.3946 | 0.3946 | 3.39 | 7.91 | 0.359 | 2.39 | 2.65 | 704,310.60 | 4.14 | 7.64 | 4.81 | 8.96 | 60.96 | 62.57 | 11.53 | 17.85 | 2.58 | 148.40 | 0.0146 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
| Zhejiang Orient Gene Biotech Co Ltd | 627.03m | -414.61m | 5.91bn | 2.23k | -- | 0.803 | -- | 9.43 | -2.05 | -2.05 | 3.11 | 36.51 | 0.065 | 0.9281 | 2.10 | 281,055.40 | -4.58 | 29.62 | -5.53 | 38.29 | 43.94 | 59.69 | -70.46 | 35.82 | 4.27 | -- | 0.0767 | 19.24 | -90.65 | 23.46 | -119.23 | -- | 121.04 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 10.78m | 13.30% |
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 3.27m | 4.03% |
| Essence Fund Co., Ltd.as of 31 Dec 2023 | 2.46m | 3.04% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023 | 1.28m | 1.57% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 1.20m | 1.48% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 690.07k | 0.85% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 583.23k | 0.72% |
| Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 2023 | 507.11k | 0.63% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 360.28k | 0.44% |
| Franklin Templeton Sealand Fund Management Co., Ltd.as of 31 Dec 2023 | 312.03k | 0.39% |
